The active categories which the new patent covers include opiate and opiate derivatives such as buprenorphine and naloxone, anti-emetics such as ondansetron and granisetron hydrochloride, analgesics such as fentanyl, anti-migraines such as triptans, and anti-diabetics.
Additionally, the polymer components covered by the patent include carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and polyethylene oxide.
MonoSol Rx president and CEO Mark Schobel said this patent covers numerous actives and polymer components, and also ensures that MonoSol Rx has process protection for the manufacturing of single and multi-layer films delivering a range of drug classifications through buccal and sublingual administration.
"Coupled with our prior patents, MonoSol Rx’s growing intellectual property portfolio offers clear competitive advantages to our current and prospective partners who view PharmFilm as an ideal vehicle for delivering small or large molecules as well as sensitive prescription drug targets," Schobel said.